The purpose of this study is to describe the use of teclistamab/talquetamab in the
treatment of patients with RRMM outside of clinical trials.

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

Relapsed/Refractory Multiple Myeloma (RRMM)

Relapsed or Refractory Multiple Myeloma

Relapsed/ Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Relapse Multiple Myeloma

Refractory Multiple Myeloma

Multiple Myeloma

Kahler's Disease

Blood Cancer

Hematologic Neoplasms

Hematologic Malignancies

Hematology

Hematological Malignancies

Teclistamab

Talquetamab

A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials

Participants' demographics and disease characteristics (age, co-morbidities, renal
function), and prior antimyeloma therapies will be reported.

ORR is defined as the percentage of patients who have a PR or better as assessed by
investigator per International Myeloma Working Group (IMWG) response criteria.

Time to first response is defined as the time between date of first dose of
teclistamab/talquetamab and the date when patient has achieved first response, as
assessed by investigator per IMWG response criteria.

Time to best response is defined as the time between date of first dose of
teclistamab/talquetamab and the date of the best response, as assessed by investigator
per IMWG response criteria.

DOR will be calculated among participants (with a PR or better response) from the date of
the first response (PR or better) to the date of first evidence of progressive disease,
as assessed by investigator per IMWG response criteria.

Number of participants with MRD negative rate will be assessed.

OS is defined as the time from the date of first dose of teclistamab/talquetamab to the
date of the participant's death.

PFS is defined as the time from the date of first dose of teclistamab/talquetamab to the
date of first evidence of progressive disease, as assessed by investigator per IMWG
response criteria, or death due to any cause, whichever occurs first.

TTNT is defined as the time from the date of first dose of teclistamab/talquetamab to the
start of the next line of antimyeloma treatment.

Incidence and severity of adverse events (AEs) including immune effector cell-associated
neurotoxicity syndrome (ICANS), cytokine release syndrome (CRS) and other AEs as well as
medications used for prophylaxis and management of adverse events will be reported.

Treatment patterns including healthcare setting and treatment schedules will be reported.

Participants with RRMM who received at least one dose of teclistamab outside of clinical
trials on or before 31 December 2022 will be enrolled in the study. The data available
from the medical records of each enrolled participant will be the collected to describe
the use of teclistamab.

Participants with RRMM who received at least one dose of teclistamab outside of clinical
trials from 01 January 2023 to 31 December 2024, inclusive will be enrolled in the study.
The data available from the medical records of each enrolled participant will be the
collected to describe the use of teclistamab.

Participants with RRMM who received at least one dose of teclistamab outside of clinical
trials from 01 January 2025 to 31 December 2025, inclusive will be enrolled in the study.
The data available from the medical records of each enrolled participant will be the
collected to describe the use of teclistamab.

Participants with RRMM who received at least one dose of talquetamab outside of clinical
trials on or before 31 December 2023 will be enrolled in the study. The data available
from the medical records of each enrolled participant will be collected to describe the
use of talquetamab.

Aalborg Sygehus Syd

Rigshospitalet

Odense University Hospital

Sygehus Lillebælt, Vejle

Hopital Albert Calmette - CHU Lille

Institut Paoli Calmettes

CHU de Nantes hotel Dieu

Hopital Saint Louis

Institut Universitaire du Cancer Toulouse Oncopole

CHRU de Nancy - Hopitaux de Brabois

Klinikum Chemnitz gGmbH

Universitatsklinikum Carl Gustav Carus Dresden

University Hospital Hamburg Eppendorf

Uniklinikum Heidelberg

Klinikum Nurnberg Nord

Universitätsklinikum Würzburg Med. Klinik U. Poliklinik Ii

University Hospital of Alexandroupolis

Cork University Hospital

St James Hospital

University Hospital Galway - Ireland

Hadassah Medical Center

Sheba Medical Center

Tel Aviv Sourasky Medical Center

Policlinico Sant'Orsola Malpighi

Ospedale A.Perrino di Brindisi

AOU Careggi

Policlinico di Milano

Azienda Ospedaliera Universitaria Federico II

Casa di Cura La Maddalena

Universita Cattolica del Sacro Cuore - Fondazione Policlinico Universitario 'A. Gemelli'

Presidio Ospedaliero Santo Spirito in Sassia

Ospedale Ca' Foncello

Azienda Sanitaria Universitaria Giuliano Isontina Ospedale Maggiore

Hosp. Ntra. Sra. de Sonsoles

Hosp. Univ. Virgen de Las Nieves

Hosp. Univ. de La Princesa

Hosp. Univ. de La Paz

Hosp. Costa Del Sol

Hosp. Alvaro Cunqueiro

Sahlgrenska University Hospital

Länssjukhuset Ryhov

Karolinska Universitetssjukhuset

Uddevalla Hospital

Queen Elizabeth Hospital

University College Hospital

Guys and St Thomas NHS Foundation Trust

The Royal Wolverhampton Hospitals NHS Trust - New Cross Hosp

Hosp. Clinico Univ. de Valencia

University Hospital of Crete, PAGNI

University Hospital Of Larissa

Ahepa University General Hospital of Thessaloniki

Ospedale Vito Fazzi

Ospedale Andrea Tortora Pagani Salerno

Ospedale San Bortolo

Akershus Universitetssykehus

Anticancer Hospital of Thessaloniki Theageneio

Azienda Sanitaria dell'Alto Adige - Ospedale di Bolzano

G Papanikolaou Hospital of Thessaloniki

Laiko General Hospital of Athens

Bon Secours Hospital

IRCCS Istituto Europeo di Oncologia

Vestfold Hospital Trust

Aarhus Universitetshospital

Ioannina University Hospital

Beacon Hospital

Ospedale Castelli

Klinikum Region Hannover Klinikum Siloah

Alexandra Hospital

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

Trials at a glance

Trials at a glance

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

Outcome measures

Primary outcome measures

Secondary outcome measures